Galapagos increases share capital through warrant exercises
(Thomson Reuters ONE) -
Mechelen, Belgium; 20 June 2017, 22.00 CET; regulated information - Galapagos NV
(Euronext & NASDAQ: GLPG) announces a share capital increase arising from
warrant exercises.
Galapagos issued 52,030 new ordinary shares on 20 June 2017, for a total capital
increase (including issuance premium) of ?631,898.90.
Pursuant to the warrant exercise program of Galapagos' executive committee,
executive committee members automatically are committed to exercise a minimum
number of warrants, subject to certain conditions. In accordance with the rules
of this program, CEO Onno van de Stolpe exercised 15,000 warrants. Two other
executive committee members exercised an aggregate number of 10,000 warrants. In
addition to Onno van de Stolpe, one other board member exercised 3,780 warrants.
In accordance with Belgian transparency legislation[1], Galapagos notes that its
total share capital currently amounts to ?275,135,922.48, the total number of
securities conferring voting rights is 50,867,678, which is also the total
number of voting rights (the "denominator"), and all securities conferring
voting rights and all voting rights are of the same category. The total number
of rights (warrants) to subscribe to not yet issued securities conferring voting
rights is 3,317,307, which equals the total number of voting rights that may
result from the exercise of these warrants. Galapagos does not have any
convertible bonds or shares without voting rights outstanding.
About Galapagos
Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company
specialized in the discovery and development of small molecule medicines with
novel modes of action. Our pipeline comprises Phase 3, 2, 1, pre-clinical and
discovery studies in cystic fibrosis, inflammation, fibrosis, osteoarthritis and
other indications. We have discovered and developed filgotinib: in collaboration
with Gilead we aim to bring this JAK1-selective inhibitor for inflammatory
indications to patients all over the world. Galapagos is focused on the
development and commercialization of novel medicines that will improve people's
lives. The Galapagos group, including fee-for-service subsidiary Fidelta, has
approximately 530 employees, operating from its Mechelen, Belgium headquarters
and facilities in The Netherlands, France, and Croatia. More information at
www.glpg.com.
Contacts
Investors: Media:
Elizabeth Goodwin Evelyn Fox
VP IR & Corporate Director Communications
Communications +31 6 53 591 999
+1 781 460 1784 communications(at)glpg.com
Paul van der Horst
Director IR & Business
Development
+31 6 53 725 199
ir(at)glpg.com
Forward-looking statements
This release may contain forward-looking statements. Such forward-looking
statements are not guarantees of future results. These forward-looking
statements speak only as of the date of publication of this document. Galapagos
expressly disclaims any obligation to update any forward-looking statements in
this document, unless specifically required by law or regulation.
--------------------------------------------------------------------------------
[1] Belgian Act of 2 May 2007 on the disclosure of major shareholdings in
issuers whose shares are admitted to trading on a regulated market
GLPG exercises warrants:
http://hugin.info/133350/R/2114613/804541.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Galapagos NV via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 20.06.2017 - 22:00 Uhr
Sprache: Deutsch
News-ID 548998
Anzahl Zeichen: 4273
contact information:
Town:
Mechelen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 175 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Galapagos increases share capital through warrant exercises"
steht unter der journalistisch-redaktionellen Verantwortung von
Galapagos NV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
